Protagonist TherapeuticsPTGX +0.78%51 Quick Ratio is 17.76 as of Mar. 2026, which is 126% above its 10-year median of 7.85. GuruFocus rates PTGX with a GF Score™ of 51/100 and a GF Value™ of $58.69 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,412 Biotechnology companies, Protagonist Therapeutics ranks better than 90.16% on this metric.
Protagonist Therapeutics has a quick ratio of 17.76. It generally indicates good short-term financial strength.
The historical rank and industry rank for Protagonist Therapeutics's Quick Ratio or its related term are showing as below:
PTGX'
s Quick Ratio Range Over the Past 10 Years
Min: 1.87 Med: 7.85 Max: 19.11
Current: 17.76
During the past 12 years, Protagonist Therapeutics's highest Quick Ratio was 19.11. The lowest was 1.87. And the median was 7.85.
PTGX's Quick Ratio is ranked better than 90.16% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs PTGX: 17.76
Protagonist Therapeutics (NAS:PTGX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Protagonist Therapeutics Quick Ratio Related Terms
Protagonist Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protagonist Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagonist Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Protagonist Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics (PTGX) has a Quick Ratio of 17.76 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Protagonist Therapeutics and its competitors. This is 126% above median its historical median of 7.85. Over the past decade, Protagonist Therapeutics' Quick Ratio has ranged from 1.87 to 19.11. According to the industry distribution chart, Protagonist Therapeutics ranks #139 out of 1412 companies in the Biotechnology industry, placing it in the top 9.8%.
Is Protagonist Therapeutics' Quick Ratio too high?
Protagonist Therapeutics' current Quick Ratio of 17.76 is 126% above median its 10-year median of 7.85. Over the past 10 years, this metric has ranged from a low of 1.87 to a high of 19.11. The Biotechnology industry median Quick Ratio is 3.60. Protagonist Therapeutics' value of 17.76 is 393.3% above this industry median. Based on the distribution chart, Protagonist Therapeutics ranks #139 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protagonist Therapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Quick Ratio compare to IMVT and SYRE?
According to the Biotechnology industry distribution chart, Protagonist Therapeutics ranks #139 out of 1412 companies for Quick Ratio. This places Protagonist Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Protagonist Therapeutics' value of 17.76 is 393.3% above this benchmark. Historically, Protagonist Therapeutics' own Quick Ratio has ranged from 1.87 to 19.11 over the past decade. While the company's 10-year median is 7.85 vs. the industry median of 3.60, Protagonist Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagonist Therapeutics's current Quick Ratio of 17.76 is 393.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Protagonist Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagonist Therapeutics's current Quick Ratio is 17.76, which is 126% above median its own 10-year median of 7.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protagonist Therapeutics (PTGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $58.69, compared to a current price of $122.58 — trading 108.9% above its estimated fair value. The current Quick Ratio is 17.76, which is 126% above median its 10-year median of 7.85 and 393.3% above the Biotechnology industry median of 3.60. Protagonist Therapeutics' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Protagonist Therapeutics (PTGX), the current Quick Ratio is 17.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protagonist Therapeutics (PTGX) Overvalued in 2026?
Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued.
The current stock price of $122.58 is trading 108.9% above its estimated GF Value™ of $58.69.
GuruFocus considers Protagonist Therapeutics to be Significantly Overvalued.
Key valuation signals for PTGX:
Quick Ratio: 17.76 (126% above median its 10-year median of 7.85)
GF Value™: $58.69 vs. price of $122.58 (108.9% above fair value)
Industry Position: 393.3% above the Biotechnology median (#139 of 1412)
No single metric tells the full story. See the PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
51GF Score
Get the complete analysis for PTGX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTGX has been successfully added to your 
